Trial reportBlood advances2018
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL.
Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.British journal of haematology · 2026Trial
- Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.Blood advances · 2025Trial
- Revealing the promising therapeutic targets and prognostic markers of primary mediastinal large B-cell lymphoma.Discover oncology · 2026Review
- Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.Hematology reports · 2025Review
- Review
- Optimizing the prognostic capacity of baselineHeliyon · 2024Article
- [Progress in treatment of primary mediastinal large B-cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?HemaSphere · 2023Article
- Quantitative PET-based biomarkers in lymphoma: getting ready for primetime.Nature reviews. Clinical oncology · 2023Review
- Development of scalable lymphatic system in the 4D XCAT phantom: Application to quantitative evaluation of lymphoma PET segmentations.Medical physics · 2022Article
- SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.Blood advances · 2022Article
- Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.Blood advances · 2022Article
- Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2021Article
- Primary mediastinal large B cell lymphoma.Thoracic cancer · 2021Review
- Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions.Frontiers in oncology · 2021Review
- Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.Haematologica · 2020Article
- Primary Mediastinal Large B-cell Lymphoma: A Diagnostic Conundrum.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Chelsea C PinnixDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Andrea K NgDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA.
Bouthaina S DabajaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sarah A MilgromDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jillian R GuntherDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
C David FullerDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Grace L SmithDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Zeinab Abou YehiaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wei QiaoDepartment of Biostatistics.
Christine F WoganDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Mani AkhtariDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Osama MawlawiDepartment of Imaging Physics.
L Jeffrey MedeirosDepartment of Hematopathology, and.
Hubert H ChuangDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
William Martin-DoyleDepartment of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; and.
Philippe ArmandDepartment of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; and.
Ann S LaCasceDepartment of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; and.
Yasuhiro OkiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michelle FanaleDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jason WestinDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sattva NeelapuDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Loretta NastoupilDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USDana-Farber Cancer Institute · USCancer Research And Biostatistics · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTargeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1MUsing Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9MSMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1MEconomic Strain and Resilience in Cancer Patients: Assessing Patient-Reported Measures of the Burdens of TreatmentK07CA211804 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SMITH, GRACE · 2016 to 2020
$853kimaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810kUsing Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR56DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2015 to 2015
$470kNCI NIH HHS K07 CA211804NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA214825NCI NIH HHS R01 CA218148NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R56 DE025248
Abstract
Dose-adjusted rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma (PMBCL), but predictors of resistance to this treatment are unclear. We investigated whether [
Indexed as
Lymphoma, B-CellMediastinal NeoplasmsModels, BiologicalPositron-Emission TomographyTomography, X-Ray ComputedAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinEtoposideFemaleHumansMaleMiddle AgedCyclophosphamideDoxorubicinEtoposideVincristine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.